---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031575"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:29:10.180766+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q3 net loss $4.0M; cash $9.8M, funds only through Q1 2023; Phase 3 ADHD trial starts Dec 2022

## Summary
- Q3 2022 net loss $4.0M vs $15.3M in Q3 2021; cash and equivalents $9.8M, expected to fund only through first quarter 2023.
- Phase 3 adult dose-optimization study for lead ADHD candidate CTx-1301 to commence December 2022; NDA submission targeted H1 2024.
- Executed Master Services Agreement with Societal CDMO to manufacture clinical, registration, and commercial batches of CTx-1301.
- Anxiety candidate CTx-2103 triple-release buspirone achieved solubility targets; clinical program design underway.
- Phase 1/2 bioavailability study for ADHD candidate CTx-1302 (dextroamphetamine) planned for first half 2024.

## SEC filing metadata
- accession: 0001493152-22-031575
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/0001493152-22-031575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031575
- JSON: https://secwatch.observer/filing/0001493152-22-031575.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031575.txt

## Key facts
- Earnings Releases
  Cingulate Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Cingulate Inc. (the “Company”) issued a press release announcing its financial results for the third quarter of 2022 and providing a clinical and business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/0001493152-22-031575-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.